Depressive SymptomsSAAFDNCT05631184

Self-administered Acupressure for Depression

A study testing Self-administered acupressure group and Mental health education group in people with Depressive Symptoms and Depressive Disorder, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The goal of this clinical trial is to examine the effects of self-administered acupressure intervention for alleviating depressive symptoms among people with depression. It is hypothesized that the self-administered acupressure group would have a great improvement in depressive symptoms as measured by the Patient… Read more about this study

Who is it for?: Ages 18 to 65 years
Conditions the study is for: Depressive Symptoms, Depressive Disorder, Depression
What is being tested?: Self-administered acupressure group and Mental health education group
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 250 participants
Where: 1 siteHong Kong
Study dates: 20 Nov 2022to 1 Sep 2024
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Hong Kong residents aged 18 to 65
Can communicate in Cantonese and comprehend written Chinese
Have moderate or above-level depression as measured by the PHQ-9 with a score of 10 or above
Willing to give informed consent and comply with the trial protocol.

Who cannot join

Have the PHQ score of 20 or above (referral information to community psychological services will be provided)
New onset or change of antidepressant medication or dosage in the last 3 months
Previous or current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder as screened using the Chinese version of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders.
Have cognitive impairment diagnosed by the Hong Kong Montreal Cognitive Assessment with a score < 22
Skin lesions or infections at the treatment sites
Significant suicidal risk as rated by the Hamilton Depression Rating Scale item on suicide (score ≥3)
Pregnant or childbearing potential but not using adequate contraception
With any major medical condition that causes depression based on the judgement of a psychiatrist.

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site

School of Nursing, the Hong Kong Polytechnic University
Hong Kong

Other trials in Hong Kong

About this study

Official title: Self-administered Acupressure for Depression: A Randomized Controlled Trial

The main questions it aims to answer are:

Is the self-administered acupressure intervention more effective for alleviating depression and other related outcomes compared to the mental health education group among depressed individuals?
Is the self-administered acupressure intervention acceptable and feasible for depressed individuals to alleviate depression? Participants will be randomized into self-administered acupressure group or mental health education group based on the group allocation with a 1:1 ratio. Participants will attend two weekly 120-min self-administered acupressure training or mental health education, respectively.

Conditions: Depressive Symptoms, Depressive Disorder, Depression
Being tested: Self-administered acupressure group, Mental health education group
Keywords: Depression, Acupressure, Randomized Controlled Trial
Medical subject headings: Depression, Depressive Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Self-administered acupressure groupBehavioural
Self-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.
Mental health education groupBehavioural
Mental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.

Study groups in NCT05631184
Study group	Role	What they receive
Self-administered acupressure group	Experimental	The participants in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 h each) to learn self-administered acupressure from an acupuncturist in a classroom at the School Nursing, the Hong Kong Polytechnic University. Each class will be conducted in a small group of 4 to 7 participants to enhance interaction and ensure the quality of teaching. Participants will then practice two times a day for 8 weeks. Receives: Behavioral: Self-administered acupressure group
Mental health education group	Active comparator	The participants in the comparison group will receive mental health education group from a registered nurse with the same frequency as those in the treatment group (2 sessions, 2 h each) in a classroom at the School Nursing, the Hong Kong Polytechnic University, and will be reminded to follow the mental health practice daily for 8 weeks. Receives: Behavioral: Mental health education group

What is being measured

The primary outcome is the main question the study is designed to answer.

Patient Health Questionnaire (PHQ)
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Measured: It will be measured at baseline
Patient Health Questionnaire (PHQ)
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Measured: It will be measured at week 4 from baseline
Patient Health Questionnaire (PHQ)
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Measured: It will be measured at week 8 from baseline
Patient Health Questionnaire (PHQ)
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Measured: It will be measured at week 12 from baseline

Secondary outcomes (20)

Hamilton Depression Rating Scale (HDRS)
The HDRS is used to assess the severity of depressive symptoms based on the 17-item scale. Eight items are scored on a 5-point scale, ranging from 0 to 4 and nine items are scored from 0 to 2. The total score varies from 0 (the minimum value) to 52 (the maximum value), with a higher total score indicating more severe depression.
Measured: It will be measured at baseline
Hamilton Depression Rating Scale (HDRS)
The HDRS is used to assess the severity of depressive symptoms based on the 17-item scale. Eight items are scored on a 5-point scale, ranging from 0 to 4 and nine items are scored from 0 to 2. The total score varies from 0 (the minimum value) to 52 (the maximum value), with a higher total score indicating more severe depression.
Measured: It will be measured at week 4 from baseline
Hamilton Depression Rating Scale (HDRS)
The HDRS is used to assess the severity of depressive symptoms based on the 17-item scale. Eight items are scored on a 5-point scale, ranging from 0 to 4 and nine items are scored from 0 to 2. The total score varies from 0 (the minimum value) to 52 (the maximum value), with a higher total score indicating more severe depression.
Measured: It will be measured at week 8 from baseline
Hamilton Depression Rating Scale (HDRS)
The HDRS is used to assess the severity of depressive symptoms based on the 17-item scale. Eight items are scored on a 5-point scale, ranging from 0 to 4 and nine items are scored from 0 to 2. The total score varies from 0 (the minimum value) to 52 (the maximum value), with a higher total score indicating more severe depression.
Measured: It will be measured at week 12 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
The DASS-21 Stress subscale will be used to measure the emotional states of stress using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
The DASS-21 Stress subscale will be used to measure the emotional states of stress using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 4 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
The DASS-21 Stress subscale will be used to measure the emotional states of stress using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 8 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
The DASS-21 Stress subscale will be used to measure the emotional states of stress using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 12 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
The DASS-21 Anxiety subscale will be used to measure the emotional states of anxiety using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
The DASS-21 Anxiety subscale will be used to measure the emotional states of anxiety using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 4 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
The DASS-21 Anxiety subscale will be used to measure the emotional states of anxiety using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 8 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
The DASS-21 Anxiety subscale will be used to measure the emotional states of anxiety using a 4-point scale ranging from 0 (never) to 3 (almost always).
Measured: It will be measured at week 12 from baseline
The Insomnia Severity Index (ISI)
The ISI is a seven-item self-rating scale to assess the severity of insomnia, distress, and functional impairment associated with insomnia on a 5-point Likert scale.
Measured: It will be measured at baseline
The Insomnia Severity Index (ISI)
The ISI is a seven-item self-rating scale to assess the severity of insomnia, distress, and functional impairment associated with insomnia on a 5-point Likert scale.
Measured: It will be measured at week 4 from baseline
The Insomnia Severity Index (ISI)
The ISI is a seven-item self-rating scale to assess the severity of insomnia, distress, and functional impairment associated with insomnia on a 5-point Likert scale.
Measured: It will be measured at week 8 from baseline
The Insomnia Severity Index (ISI)
The ISI is a seven-item self-rating scale to assess the severity of insomnia, distress, and functional impairment associated with insomnia on a 5-point Likert scale.
Measured: It will be measured at week 12 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
The SF-6D covers six domains using a scale of 1 to 6 to evaluate participants' general health and quality of life.
Measured: It will be measured at baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
The SF-6D covers six domains using a scale of 1 to 6 to evaluate participants' general health and quality of life.
Measured: It will be measured at week 4 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
The SF-6D covers six domains using a scale of 1 to 6 to evaluate participants' general health and quality of life.
Measured: It will be measured at week 8 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
The SF-6D covers six domains using a scale of 1 to 6 to evaluate participants' general health and quality of life.
Measured: It will be measured at week 12 from baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

20 Nov 20221 Sep 2024

First posted30 Nov 2022
Study start20 Nov 2022
Primary completion19 Aug 2024
Study completion1 Sep 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (5)Papers the sponsor has linked to this study.
Other trials for Depressive SymptomsStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Two-arm parallel assignment involves two groups of participants. In this study, one group will receive self-administered acupressure, and the other group will receive the mental health education. So during the trial, participants in one group receive self-administered acupressure "in parallel" to participants in the other group, who receive the mental health education.
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 250 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05631184
Sponsor's protocol ID: SelfAcupDep
Other IDs: 19200171
Acronym: SAAFD
Status last verified: Feb 2024
First submitted: 14 Nov 2022
Last updated: 22 Sep 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: The individual participant data will be available when the study has been published. The individual participant data will be available upon request.

Publications

Zhang Z, Li S, Meng H, Wang Y, Zhang Y, Wu M, Chen Y, Rong P, Wang Y. Efficacy and safety of acupuncture in the treatment of depression: A systematic review of clinical research. Anat Rec (Hoboken). 2021 Nov;304(11):2436-2453. doi: 10.1002/ar.24783. Epub 2021 Oct 8.
PubMed 34623754
Fernandez-Chinguel JE, Goicochea-Lugo S, Villarreal-Zegarra D, Taype-Rondan A, Zafra-Tanaka JH. Acupuncture for major depressive disorder: A review of the recommendations stated at clinical practice guidelines. Complement Ther Med. 2020 Mar;49:102321. doi: 10.1016/j.ctim.2020.102321. Epub 2020 Jan 24.
PubMed 32147048
Cheung DST, Tiwari A, Yeung WF, Yu DSF, So MKP, Chau PH, Wang XM, Lum TYS, Yuk Fung HYK, Ng BYM, Zhang ZJ, Lao L. Self-Administered Acupressure for Caregivers of Older Family Members: A Randomized Controlled Trial. J Am Geriatr Soc. 2020 Jun;68(6):1193-1201. doi: 10.1111/jgs.16357. Epub 2020 Feb 25.
PubMed 32096884
Kroenke K. Enhancing the clinical utility of depression screening. CMAJ. 2012 Feb 21;184(3):281-2. doi: 10.1503/cmaj.112004. Epub 2012 Jan 9. No abstract available.
PubMed 22231681
Yeung WF, Yu BYM, Ho FY, Wong CKH, Chung KF, Ruan JY, Chen S, Cheung DST, Zhang ZJ, Zick S, Cheng H, Ho YS, Ho LM, Lao L. Self-administered acupressure training for depression in community-dwelling individuals: a randomized controlled trial and cost-effectiveness analysis. EClinicalMedicine. 2026 Jun 16;96:104023. doi: 10.1016/j.eclinm.2026.104023. eCollection 2026 Jun.
PubMed 42339308

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 2
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
RecruitingPhase 1
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Healthy Volunteer, Major Depressive Disorder
RecruitingPhase 1
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Vasopressin Deficiency
Recruiting
Psychopharmacotherapy for Depressive Patients
Major Depressive Disorder
RecruitingObservational study
Characterization and Treatment of Adolescent Depression
Depression

All Depressive Symptoms trials

Study at a glance

From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Self-administered Acupressure for Depression: A Randomized Controlled Trial
ClinicalTrials.gov ID: NCT05631184
Acronym / sponsor ID: SAAFD / SelfAcupDep
Conditions: Depressive Symptoms, Depressive Disorder, Depression
Keywords: Depression, Acupressure, Randomized Controlled Trial
Study type: Interventional
Recruitment status: Completed
Enrolment: 250 participants (actual)
Lead sponsor: The Hong Kong Polytechnic UniversityUniversity, hospital or other
Collaborators: Health and Medical Research Fund
Study start: 20 Nov 2022 (actual)
Primary completion: 19 Aug 2024 (actual)
Study completion: 1 Sep 2024 (actual)
First posted: 30 Nov 2022 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The main questions it aims to answer are:

Is the self-administered acupressure intervention more effective for alleviating depression and other related outcomes compared to the mental health education group among depressed individuals?
Is the self-administered acupressure intervention acceptable and feasible for depressed individuals to alleviate depression? Participants will be randomized into self-administered acupressure group or mental health education group based on the group allocation with a 1:1 ratio. Participants will attend two weekly 120-min self-administered acupressure training or mental health education, respectively.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind (outcomes assessor)
Number of arms: 2
Model description: Two-arm parallel assignment involves two groups of participants. In this study, one group will receive self-administered acupressure, and the other group will receive the mental health education. So during the trial, participants in one group receive self-administered acupressure "in parallel" to participants in the other group, who receive the mental health education.

Arm	Type	Receives
Self-administered acupressure group	Experimental	Behavioral: Self-administered acupressure groupThe participants in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 h each) to learn self-administered acupressure from an acupuncturist in a classroom at the School Nursing, the Hong Kong Polytechnic University. Each class will be conducted in a small group of 4 to 7 participants to enhance interaction and ensure the quality of teaching. Participants will then practice two times a day for 8 weeks.
Mental health education group	Active comparator	Behavioral: Mental health education groupThe participants in the comparison group will receive mental health education group from a registered nurse with the same frequency as those in the treatment group (2 sessions, 2 h each) in a classroom at the School Nursing, the Hong Kong Polytechnic University, and will be reminded to follow the mental health practice daily for 8 weeks.

Who may qualify

Ages: 18 to 65 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Hong Kong residents aged 18 to 65
Can communicate in Cantonese and comprehend written Chinese
Have moderate or above-level depression as measured by the PHQ-9 with a score of 10 or above
Willing to give informed consent and comply with the trial protocol.

Key exclusion criteria (8 listed)

Have the PHQ score of 20 or above (referral information to community psychological services will be provided)
New onset or change of antidepressant medication or dosage in the last 3 months
Previous or current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder as screened using the Chinese version of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders.
Have cognitive impairment diagnosed by the Hong Kong Montreal Cognitive Assessment with a score < 22
Skin lesions or infections at the treatment sites

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Self-administered acupressure groupSelf-administered acupressure treatment group was developed on the basis of previous systematic reviews and clinical studies of acupuncture and acupressure for depression. It has robust theoretical basis of TCM. The acupoints selected are commonly used for depression according to a recent systematic review and recommended by other clinical practice guidelines.	Behavioural	Self-administered acupressure group
Mental health education groupMental health education training group was developed based on the materials regarding depression and mental health from the Centre of Health Protection, Department of Health, the Government of Hong Kong SAR and reviewed by a clinical psychologist.	Behavioural	Mental health education group

Primary outcome

Patient Health Questionnaire (PHQ)
Time frame: It will be measured at baseline
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Patient Health Questionnaire (PHQ)
Time frame: It will be measured at week 4 from baseline
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Patient Health Questionnaire (PHQ)
Time frame: It will be measured at week 8 from baseline
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.
Patient Health Questionnaire (PHQ)
Time frame: It will be measured at week 12 from baseline
The PHQ-9, a self-rated questionnaire to assess depressive symptoms over the last 2 weeks on a scale of 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27.

20 secondary outcomes

Hamilton Depression Rating Scale (HDRS)
Time frame: It will be measured at baseline
Hamilton Depression Rating Scale (HDRS)
Time frame: It will be measured at week 4 from baseline
Hamilton Depression Rating Scale (HDRS)
Time frame: It will be measured at week 8 from baseline
Hamilton Depression Rating Scale (HDRS)
Time frame: It will be measured at week 12 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
Time frame: It will be measured at baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
Time frame: It will be measured at week 4 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
Time frame: It will be measured at week 8 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Stress
Time frame: It will be measured at week 12 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
Time frame: It will be measured at baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
Time frame: It will be measured at week 4 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
Time frame: It will be measured at week 8 from baseline
The Depression Anxiety Stress Scales (DASS-21) - Anxiety
Time frame: It will be measured at week 12 from baseline
The Insomnia Severity Index (ISI)
Time frame: It will be measured at baseline
The Insomnia Severity Index (ISI)
Time frame: It will be measured at week 4 from baseline
The Insomnia Severity Index (ISI)
Time frame: It will be measured at week 8 from baseline
The Insomnia Severity Index (ISI)
Time frame: It will be measured at week 12 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
Time frame: It will be measured at baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
Time frame: It will be measured at week 4 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
Time frame: It will be measured at week 8 from baseline
The Short-Form (six-dimension) Health Survey (SF-6D)
Time frame: It will be measured at week 12 from baseline

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
Background: PubMed 34623754Zhang Z, Li S, Meng H, Wang Y, Zhang Y, Wu M, Chen Y, Rong P, Wang Y. Efficacy and safety of acupuncture in the treatment of depression: A systematic review of clinical research. Anat Rec (Hoboken). 2021 Nov;304(11):2436-2453. doi: 10.1002/ar.24783. Epub 2021 Oct 8.
Background: PubMed 32147048Fernandez-Chinguel JE, Goicochea-Lugo S, Villarreal-Zegarra D, Taype-Rondan A, Zafra-Tanaka JH. Acupuncture for major depressive disorder: A review of the recommendations stated at clinical practice guidelines. Complement Ther Med. 2020 Mar;49:102321. doi: 10.1016/j.ctim.2020.102321. Epub 2020 Jan 24.
Background: PubMed 32096884Cheung DST, Tiwari A, Yeung WF, Yu DSF, So MKP, Chau PH, Wang XM, Lum TYS, Yuk Fung HYK, Ng BYM, Zhang ZJ, Lao L. Self-Administered Acupressure for Caregivers of Older Family Members: A Randomized Controlled Trial. J Am Geriatr Soc. 2020 Jun;68(6):1193-1201. doi: 10.1111/jgs.16357. Epub 2020 Feb 25.
Background: PubMed 22231681Kroenke K. Enhancing the clinical utility of depression screening. CMAJ. 2012 Feb 21;184(3):281-2. doi: 10.1503/cmaj.112004. Epub 2012 Jan 9. No abstract available.
Derived from this study: PubMed 42339308Yeung WF, Yu BYM, Ho FY, Wong CKH, Chung KF, Ruan JY, Chen S, Cheung DST, Zhang ZJ, Zick S, Cheng H, Ho YS, Ho LM, Lao L. Self-administered acupressure training for depression in community-dwelling individuals: a randomized controlled trial and cost-effectiveness analysis. EClinicalMedicine. 2026 Jun 16;96:104023. doi: 10.1016/j.eclinm.2026.104023. eCollection 2026 Jun.
Individual participant dataSharing planned: Yes. The individual participant data will be available when the study has been published. The individual participant data will be available upon request.

Related trials for Depressive Symptoms

RecruitingPhase 2
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
RecruitingPhase 1
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Healthy Volunteer, Major Depressive Disorder
RecruitingPhase 1
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
Vasopressin Deficiency
Recruiting
Psychopharmacotherapy for Depressive Patients
Major Depressive Disorder
RecruitingObservational study
Characterization and Treatment of Adolescent Depression
Depression

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Wing Fai Yeung, PhD principal investigator

the School of Nursing, the Hong Kong Polytechnic University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient Health Questionnaire (PHQ) (time frame: It will be measured at baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05631184, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.